PRDX5 was also found to be related to several clinical aspects such as prognosis in various molecular subtypes, responses to chemotherapy, and androgen receptor signaling inhibitor (ARSI) therapy in PCa. The gene discussed is PRDX5; the disease is posterior cortical atrophy.